These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10636162)

  • 1. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
    Nutt JG; Carter JH
    Neurology; 2000 Jan; 54(1):247-50. PubMed ID: 10636162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of Parkinson's disease.
    Münchau A; Bhatia KP
    Postgrad Med J; 2000 Oct; 76(900):602-10. PubMed ID: 11009573
    [No Abstract]   [Full Text] [Related]  

  • 4. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of apomorphine in clinical practice.
    MacMahon DG
    Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
    [No Abstract]   [Full Text] [Related]  

  • 7. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ; Sesar-Ignacio Á
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ; Kulisevsky J
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine in dopaminergic therapy.
    Subramony JA
    Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of apomorphine in movement disorders.
    Colosimo C; Merello M; Albanese A
    Clin Neuropharmacol; 1994 Jun; 17(3):243-59. PubMed ID: 9316670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and therapeutic value of apomorphine in Parkinsonian patients.
    Sharma JC; Macnamara L; Hasoon M; Vassallo M
    Int J Clin Pract; 2004 Nov; 58(11):1028-32. PubMed ID: 15605666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR; Mata M
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa.
    Schwarz J; Oertel WH; Tatsch K
    J Nucl Med; 1996 Jul; 37(7):1112-5. PubMed ID: 8965179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-duration action of levodopa may be due to a postsynaptic effect.
    Barbato L; Stocchi F; Monge A; Vacca L; Ruggieri S; Nordera G; Marsden CD
    Clin Neuropharmacol; 1997 Oct; 20(5):394-401. PubMed ID: 9331515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.
    Kim HJ; Jeon BS; Jenner P
    Int Rev Neurobiol; 2017; 132():295-343. PubMed ID: 28554412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract]   [Full Text] [Related]  

  • 18. Unexpected findings with apomorphine and their possible consequences.
    Cotzias GC; Mena I; Papavasiliou PS; Mendez J
    Adv Neurol; 1974; 5():295-9. PubMed ID: 4440577
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
    Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: drug therapy.
    Oertel WH; Quinn NP
    Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.